Financial Survey: Pulse Biosciences (NASDAQ:PLSE) versus STERIS (NYSE:STE)

Pulse Biosciences (NASDAQ:PLSE) and STERIS (NYSE:STE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Pulse Biosciences and STERIS”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	3,984.16	-$72.78 million	($1.08)	-18.99
STERIS	$5.46 billion	3.95	$614.64 million	$7.17	30.65

STERIS has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

76.9% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 74.6% of Pulse Biosciences shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pulse Biosciences and STERIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-73.77%	-63.98%
STERIS	12.15%	14.34%	9.58%

Volatility & Risk

Pulse Biosciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, STERIS has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Pulse Biosciences and STERIS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	2	0	2.33
STERIS	0	1	6	0	2.86

Pulse Biosciences currently has a consensus price target of $30.00, indicating a potential upside of 46.27%. STERIS has a consensus price target of $275.20, indicating a potential upside of 25.24%. Given Pulse Biosciences’ higher probable upside, equities analysts plainly believe Pulse Biosciences is more favorable than STERIS.

Summary

STERIS beats Pulse Biosciences on 10 of the 14 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.